Cethromycin Achieves All Endpoints In Second Pivotal Phase III Trial For Treatment For Pneumonia

Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), has announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States. [click link for full article]

More: continued here

Filed under: Infectious Diseases / Bacteria / Viruses on November 18th, 2007